CONMED Corporation

Equities

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2025-06-12 pm EDT			5-day change	1st Jan Change
54.97 ^USD	-3.48%		-2.91%	-19.68%

Jun. 12	Conmed Shares Fall After Needham Downgrade	MT
Jun. 12	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 3, 2025

Published on 05/21/2025 at 09:51

CONMED Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025.

Latest news about CONMED Corporation

Conmed Shares Fall After Needham Downgrade	Jun. 12	MT
Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	Jun. 12	MT
CONMED Corporation, Q1 2025 Earnings Call, Apr 30, 2025	May. 26
CONMED Names LaVerne Council as Board Chair	May. 21	MT
Conmed Corporation Appoints Laverne Council As Chair Of The Board Of Directors	May. 21	RE
Conmed Corporation Announces Changes in Chair of the Board of Directors, Effective May 21, 2025	May. 21	CI
Tranche Update on CONMED Corporation's Equity Buyback Plan announced on February 15, 2005.	May. 01	CI
Earnings Flash (CNMD) CONMED CORPORATION Reports Q1 Revenue $321.3M, vs. FactSet Est of $313.4M	Apr. 30	MT
Earnings Flash (CNMD) CONMED CORPORATION Posts Q1 Adjusted EPS $0.95, vs. FactSet Est of $0.81	Apr. 30	MT
Conmed Corporation Revises Earnings Guidance for Full Year 2025	Apr. 30	CI
Conmed Corporation Provides Earnings Guidance for the Second Half of 2025	Apr. 30	CI
CONMED Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 30	CI
Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	Apr. 28	MT
Conmed Corporation Announces Board Changes	Apr. 01	CI
CONMED Corporation Appoints Mark Kaye to Its Board of Directors	Feb. 25	CI
Tranche Update on CONMED Corporation's Equity Buyback Plan announced on February 15, 2005.	Feb. 18	CI
JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	Feb. 06	MT
CONMED Corporation, Q4 2024 Earnings Call, Feb 05, 2025	Feb. 05
Earnings Flash (CNMD) CONMED CORPORATION Posts Q4 Adjusted EPS $1.34, vs. FactSet Est of $1.20	Feb. 05	MT
Earnings Flash (CNMD) CONMED CORPORATION Posts Q4 Revenue $345.9M, vs. FactSet Est of $341.0M	Feb. 05	MT
CONMED Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 05	CI
CONMED Corporation Provides Financial Guidance for the First Quarter and Full Year of 2025	Feb. 05	CI
CONMED Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04:30 PM	Jan. 13
Tranche Update on CONMED Corporation's Equity Buyback Plan announced on February 15, 2005.	24-10-31	CI
Earnings Flash (CNMD) CONMED CORPORATION Reports Q3 EPS $1.05	24-10-30	MT

Chart CONMED Corporation

Duration

Period

CNMD: Dynamic Chart

Company Profile

CONMED Corporation is a medical technology company, which provides surgical devices and equipment for minimally invasive procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine and lower extremities instrumentation and implants, small bone, large bone, and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures and fees related to the sales representation, promotion, and marketing of sports medicine allograft tissue. General surgery consists of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

Employees

3,900

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-06-12 - Détachement de

More about the company